Copyright
©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 31-42
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.31
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.31
Table 1 General recommendations for the management of breast cancer
| High priority | Comments |
| (1) Choose regimens and therapeutic sequences consistent with the current situation to reduce the risk of COVID-19 in patients and health workers (Yes: 100%, No: 0%); (2) Differentiated triage for COVID-19 in all cancer centers before entrance (Yes: 100%, No: 0%); (3) Leave a medical register (informed consent) about the discussion of risk/benefits of treatments as well as therapeutic decisions and alternatives available (Yes: 78%, No: 22%); and (4) Individualize the need for blood transfusions when strictly necessary (Yes: 89%, No: 11%) | (1) These recommendations will be adapted according to the reality of each oncological center; (2) Treatment decisions are based on protocols (international/local) about the management of COVID-19; and (3) Multidisciplinary web meetings are recommended to decide the best choices of treatments and outcomes |
- Citation: Valencia GA, Neciosup S, Gómez HL, Benites MDP, Falcón S, Moron D, Veliz K, Maldonado M, Auqui R. Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. World J Clin Oncol 2021; 12(1): 31-42
- URL: https://www.wjgnet.com/2218-4333/full/v12/i1/31.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i1.31